Rapport Therapeutics

RAPP

Market cap $1.38B

BOSTON and SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological and psychiatric disorders, today announced that management plans to participate in the following upcoming investor events: TD Cowen 46 th Annual Healthcare Conference (Boston, MA) – presentation and fireside chat on Tuesday, March 3, 2026, at 3:10-3:40 pm ET. The Citizens Life Sciences Conference (Miami, FL) – presentation on Tuesday, March 10, 2026, at 2:15 pm ET.

OSAKA, Japan--(BUSINESS WIRE)-- #anime--The English Ver of Fantôme Rapport launches Jan 16, 2026 (JST). A romantic horror mystery aboard a ghostly luxury liner, where bonds shape your fate.

U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated initiation of Phase 3 program expected in the second quarter of 2026  On strength of RAP-219 Phase 2a FOS data, epilepsy portfolio expanded with new program in primary generalized tonic-clonic seizures (PGTCS) Phase 2 trial in bipolar mania, long-acting injectable, and other pipeline programs continuing to progress BOSTON and SAN DIEGO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological and psychiatric disorders, today announced plans to initiate its Phase 3 program for RAP-219 in FOS in the second quarter of 2026 and expand its epilepsy portfolio with a new program in PGTCS. Additionally, the Company announced progress across its pipeline, including its Phase 2 bipolar mania trial, long-acting injectable development, FDA's removal of the clinical hold on its Phase 2 diabetic peripheral neuropathic pain (DPNP) trial, and advancement of additional pipeline programs.

Cormorant Asset Management added 251,600 shares in Rapport Therapeutics; the reported position value increased by approximately $61.38 million over the prior quarter. The change represents 0.31% of Cormorant's reportable 13F assets under management.

BOSTON and SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological and psychiatric disorders, today announced that management plans to present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 11:15 a.m.

Does Rapport Therapeutics, Inc. (RAPP) have what it takes to be a top stock pick for momentum investors? Let's find out.

Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire treatment period, along with consistent efficacy data regardless of patients' disease severity

The consensus price target hints at a 75% upside potential for Rapport Therapeutics, Inc. (RAPP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

BOSTON and SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that the Company will present the results of its Phase 2a trial of RAP-219 in focal onset seizures (FOS), along with new efficacy analysis, at the upcoming 2025 American Epilepsy Society (AES) Annual Meeting, taking place December 5–9, 2025, in Atlanta. The Company will present during the meeting's poster sessions and will also host a dedicated Scientific Exhibit Room highlighting the RAP-219 clinical program.

The average of price targets set by Wall Street analysts indicates a potential upside of 104.5% in Rapport Therapeutics, Inc. (RAPP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.